Literature DB >> 14996877

Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.

Benjamin A Alman1, S Naweed Raza, W Douglas Biggar.   

Abstract

BACKGROUND: Scoliosis due to progressive muscle weakness occurs in almost all males with Duchenne muscular dystrophy, and it progresses relentlessly. Previous studies have shown that corticosteroid treatment slows the decline in muscle strength and stabilizes muscle strength in patients with this disease. We hypothesized that steroids may also attenuate the development of scoliosis. The purpose of this study was to compare the prevalence of scoliosis in male patients with Duchenne muscular dystrophy who received steroids with a control group of such patients who did not.
METHODS: A group of seven to ten-year-old boys with Duchenne muscular dystrophy who were able to walk were enrolled in a nonrandomized comparative study to determine the effect of deflazacort (a derivative of prednisone) on muscle strength and pulmonary function. Thirty patients were treated with deflazacort (treatment group), and twenty-four were not (control group). The patients were matched for age and pulmonary function at baseline. To assess the development of scoliosis, the patients in each group were followed for at least five years. Survival curves were plotted to determine the chance of scoliosis of >/==" BORDER="0">20 degrees developing. The difference between the groups with respect to the chance of scoliosis developing was determined with Kaplan-Meier analysis.
RESULTS: A curve of >/==" BORDER="0">20 degrees developed during the follow-up period in sixteen (67%) of the twenty-four patients in the control group but in only five (17%) of the thirty patients in the treatment group. Fifteen of the twenty-four patients in the control group underwent spine surgery, at a mean age of thirteen years, whereas only five of the thirty patients in the treatment group underwent spine surgery, at a mean age of fifteen years. Kaplan-Meier analysis demonstrated a significant difference between the two groups with regard to development of scoliosis of >/==" BORDER="0">20 degrees (p < 0.001). Cataracts developed in ten patients in the treatment group, and stress fractures developed in three patients in the treatment group. Patients in the treatment group weighed a mean of 3.7 kg more than did those in the control group.
CONCLUSIONS: Steroid treatment slows the progression of scoliosis in males with Duchenne muscular dystrophy; however, longer-term evaluation will be necessary to determine if the treatment prevents the development of scoliosis or just delays its onset. At the very least, steroid treatment delays the need for spinal surgery. LEVEL OF EVIDENCE: Therapeutic study, Level II-1 (prospective cohort study). See Instructions to Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996877     DOI: 10.2106/00004623-200403000-00009

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  26 in total

Review 1.  Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; David R Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-02       Impact factor: 3.243

Review 2.  Approaching a new age in Duchenne muscular dystrophy treatment.

Authors:  Kathryn R Wagner
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

3.  Current treatment and management of dystrophinopathies.

Authors:  Nathalie Goemans; Gunnar Buyse
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

Review 4.  Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.

Authors:  Jennifer M Bell; Michael D Shields; Janet Watters; Alistair Hamilton; Timothy Beringer; Mark Elliott; Rosaline Quinlivan; Sandya Tirupathi; Bronagh Blackwood
Journal:  Cochrane Database Syst Rev       Date:  2017-01-24

5.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

6.  Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy.

Authors:  Anne M Connolly; Elizabeth C Malkus; Jerry R Mendell; Kevin M Flanigan; J Philip Miller; Jeanine R Schierbecker; Catherine A Siener; Paul T Golumbek; Craig M Zaidman; Craig M Mcdonald; Linda Johnson; Alina Nicorici; Peter I Karachunski; John W Day; Jason M Kelecic; Linda P Lowes; Lindsay N Alfano; Basil T Darras; Peter B Kang; Janet Quigley; Amy E Pasternak; Julaine M Florence
Journal:  Muscle Nerve       Date:  2015-02-11       Impact factor: 3.217

7.  Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.

Authors:  Molly M Lamb; Nancy A West; Lijing Ouyang; Michele Yang; David Weitzenkamp; Katherine James; Emma Ciafaloni; Shree Pandya; Carolyn DiGuiseppi
Journal:  J Pediatr       Date:  2016-03-30       Impact factor: 4.406

8.  The effect of steroid treatment on weight in nonambulatory males with Duchenne muscular dystrophy.

Authors:  Molly M Lamb; Bo Cai; Julie Royer; Shree Pandya; Aida Soim; Rodolfo Valdez; Carolyn DiGuiseppi; Katherine James; Nedra Whitehead; Holly Peay; Swamy Y Venkatesh; Dennis Matthews
Journal:  Am J Med Genet A       Date:  2018-09-26       Impact factor: 2.802

9.  Sibling concordance for clinical features of Duchenne and Becker muscular dystrophies.

Authors:  Sydney Pettygrove; Zhenqiang Lu; Jennifer G Andrews; F John Meaney; Daniel W Sheehan; Elinora T Price; Deborah J Fox; Shree Pandya; Lijing Ouyang; Susan D Apkon; Zoe Powis; Christopher Cunniff
Journal:  Muscle Nerve       Date:  2014-06       Impact factor: 3.217

Review 10.  Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  David Gloss; Richard T Moxley; Stephen Ashwal; Maryam Oskoui
Journal:  Neurology       Date:  2016-02-02       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.